JPMorgan lowered the firm’s price target on Novartis to CHF 90 from CHF 95 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Novartis executes separation of Sandoz business to create independent company
- Novartis (NYSE:NVS) Completes its Generic Pharmaceutical Unit’s Spinoff
- Eli Lilly deal for Point puts radiopharma names in spotlight
- Novartis weighing sale of assets from radiopharma unit, Bloomberg says
- Novartis weighs selling part of radiopharmaceuticals unit, Bloomberg says